A biotech company comprised of scientists from the University of Bristol is launching a bid to start a clinical trial of a nasal spray treatment for the coronavirus. Halo Therapeutics wants to commercialise their discovery of a molecule which their research says changes the shape of the COVID-19 virus’s spike protein, preventing it from human entering cells. The company says its studies indicate the treatments should work against all known variants of the coronavirus , including the highly contagious UK, South African, and Brazilian ones. The scientists’ previous research found that exposing the coronavirus to the free fatty acid called “linoleic acid” effectively leaves the spike protein locked into a non-infective form. Linoleic acid is naturally occurring in the body, but it is not produced internally, instead being absorbed through our diet. Advertisement Published in the journal Science Magazine last November, the team found that when supplemented with the drug Remdesivir, the fatty acid was capable of suppressing virus replication. The company now aims to run multiple, parallel Phase II clinical trials to test these treatments, including a nasal spray and asthma-type inhaler, to identify whether they are safe and how well they work. More from Covid-19 COVID-19: Pints, parmos,… Read full this story
- What Are Swollen Nasal Passages?
- Nasal Polyps: Causes, Symptoms, and Treatments
- Nosebleeds: Causes, Home Remedies, and Prevention Tips
- Scientists reveal how herpes virus hijacks and hides in our cells
- Why does type 1 diabetes kill some cells but not others?
- Are stem cells and regenerative medicine living up to their promises?
- SARS: Causes, symptoms, and prevention
- Common Colds: Symptoms, Treatments, Prevention
- Toss the Tissue! 10 Foods That Prevent Spring Allergies
- Prevention Natural Beauty Awards 2017
COVID-19: Nasal spray could prevent coronavirus invading human cells have 270 words, post on news.sky.com at April 13, 2021. This is cached page on Europe Breaking News. If you want remove this page, please contact us.